Janney Reiterates Buy On uniQure As Firm 'Would Be Buyers On Today's Weakness' As Firm Believes Co. Should Have 'the first FDA approval for an AAV gene therapy for hemophilia B, 2) the first AAV gene therapy program in the clinic for Huntingon's'
Benzinga_Newsdesk